faculty disclosure
DESCRIPTION
Faculty Disclosure. - PowerPoint PPT PresentationTRANSCRIPT
Faculty Disclosure
In accordance with ACCME guidelines, any individual in a position to influence and/or control the content of this ASCP CME activity has disclosed all relevant financial relationships within the past 12 months with commercial interests that provide products and/or services related to the content of this CME activity.
The individual below has responded that he/she has no relevant financial relationship(s) with commercial interest(s) to disclose:
William K. Funkhouser, MD PhD
Molecular Pathology: The Future
Wm. K. Funkhouser, MD PhDUNC Pathology & Lab Medicine
Our Future Pathology Practice will be:
Citius - FasterAltius - HigherFortius - Stronger
Citius - Faster
Faster Transfer from Discovery to Practice
Galen to Harvey: Millennium Scurvy to citrus on ships: Century PCN to production: Decades HER2 amp, EGFR muts to Rx: Years ASCO meets annually….
Faster Technology
Automation of chemistry
Miniaturization of chemistry
Computer analysis of data
Faster Risk Estimates
For clinically unaffected individuals:
Etiologic mutation screening for couples Etiologic mutation screening of relatives
Faster Diagnosis
Molecular subtypes
Specific translocations
Germline etiologic mutations
Faster Prognosis
HemochromatosisA1AT deficiencyCystic fibrosis
Medullary thyroid Ca in MEN2 MMR-defective colorectal Ca
Faster Prediction of Therapeutic ResponseIndividual differences in drug metabolism
“Druggable” mutant protein kinases ID of resistance mutations
Faster Detection of Copy Number Variation
Gene Amplification
Allelic Loss
Multiplex testing
ISH
Faster Translocation Detection
Metaphase spreads
Locus-specific probes
Faster Sequence Variation Detection
Prenatal/Newborn screeningHLA loci Germline vs. neoplasm mutsFusion partners Clonal Ig or TCR
Faster Epigenetic Testing
Histone protein modification
DNA promoter methylation
Imprinting abnormalities
Faster RNA Abundance Cluster Analysis
mRNAs µRNAs
Their equilibria
Altius - Higher
Higher Complexity
Multi-analyte tests
Traits
Statistics
Higher Confidence
Risk prediction
Diagnostic, prognostic, predictive
Management guidance
Higher Productivity
Timely reporting of accurate diagnoses with useful predictive data
Prompt guidance of the treating clinician, particularly re. expensive targeted therapies
Fortius - Stronger
Stronger Associations
Statistical associations
Organizational associations
Stronger Opinions
Education of lawyers, legislators, judges, and payors
Stronger Conclusions
Better diagnostic reproducibilityBetter diagnostic accuracyBetter outcome prediction Better management guidance
.
Going forward, Molecular Pathology will
Improve our understanding of disease risk, etiology, pathogenesis, and outcomes
Complement morphology
Benefit our patients, our treating clinicians, and ourselves
Thanks to:
Drs. Myers, Humphrey, DeYoung (ADASP Leaders)Drs. Eberhard, Sepulveda, and Pfeifer (Speakers)Drs. Gulley, Weck, Tsongalis, and Nowak (AMP)
You, for participating in this ADASP meeting